USFDA approval granted for this Kidney Disease Drug

Calliditas CEO Renee Lucander anticipates that full USFDA approval will lead to a substantial increase in Tarpeyo's reach

The Health Master

December 21, 2023

128

Table of Contents

Last Updated on October 6, 2024 by The Health Master

USFDA approval

The U.S. Food and Drug Administration (USFDA) has granted full USFDA approval to Swedish drugmaker Calliditas Therapeutics’ groundbreaking drug, Tarpeyo, for the treatment of IgA Nephropathy (IgAN).

This marks a significant milestone, positioning Tarpeyo as the first drug to receive full USFDA approval in the United States for IgAN, surpassing its competitor Filspari, which received accelerated approval earlier this year.

Follow us on WhtasApp Channel

What is IgA Nephropathy (IgAN)?

IgA Nephropathy, commonly known as Berger’s disease, is a rare kidney disease characterized by the buildup of a specific type of antibody deposit in the kidneys.

This deposition leads to inflammation, causing damage to the tiny filtering units of the kidneys.

With an estimated 130,000-150,000 affected individuals in the United States, IgAN represents a critical area of medical concern.

Tarpeyo: The Breakthrough Drug

Tarpeyo, developed by Calliditas Therapeutics, has been at the forefront of IgAN treatment.

Previously accelerated USFDA granted for Tarpeyo in 2021, specifically for adults with primary IgAN experiencing increased protein levels in the urine, a condition known as proteinuria.

The recent full approval signifies a monumental step forward, providing Tarpeyo access to a significantly larger patient population.

Click for more articles on USFDA

Accelerated Approval vs. Full Approval

Accelerated approval and full approval are two distinct regulatory pathways.

While accelerated approval allows early access to promising drugs based on preliminary evidence, full approval requires comprehensive data demonstrating safety and efficacy.

The shift from accelerated to full approval positions Tarpeyo as a more established and trustworthy option for IgAN treatment.

Patient Population Expansion

Calliditas CEO Renee Lucander anticipates that full USFDA approval will lead to a substantial increase in Tarpeyo’s reach.

A larger patient population can now benefit from this innovative treatment, potentially improving outcomes for individuals grappling with IgAN.

Understanding IgAN

IgAN, or Berger’s disease, manifests as an immune system malfunction, leading to kidney inflammation.

The comprehensive understanding of this disease is crucial for appreciating the significance of Tarpeyo’s USFDA approval in addressing its underlying causes.

Tarpeyo Pricing and Accessibility

Despite the full approval, Tarpeyo’s pricing remains at $15,123 per month, distinguishing it from its competitor Filspari priced at $9,900 per month.

This pricing decision prompts considerations regarding the financial implications for patients and the broader healthcare system.

Market Reaction: Calliditas’ Stock Surge

The USFDA’s announcement triggered a remarkable 29% surge in Calliditas’ U.S.-listed shares, indicating a positive market response to Tarpeyo’s full approval.

This surge reflects investor confidence in the drug’s potential impact on the IgAN treatment landscape.

Future Projections: H.C. Wainwright Analyst’s Insights

H.C. Wainwright analyst Arthur He foresees Tarpeyo reaching a potential inflection point in its adoption by 2024.

He estimates the drug’s net sales to be around $224 million in the same year, underlining the promising future that awaits this groundbreaking treatment.

Clinical Data and Approval Basis

The full USFDA approval of Tarpeyo is grounded in robust data from a late-stage trial, demonstrating a significant improvement in filtration rate—an essential indicator of kidney health—when compared to a placebo.

This data reinforces the drug’s efficacy and justifies its complete approval.

While Tarpeyo takes center stage with its full USFDA approval, other pharmaceutical giants such as Roche, Novartis, and Vera Therapeutics are actively engaged in mid-to-late stage development trials for IgAN treatments.

The competition underscores the urgency and importance of addressing this rare kidney disease.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

FAQs

What is IgA Nephropathy?
- IgA Nephropathy, or Berger’s disease, is a rare kidney disease characterized by antibody deposits leading to inflammation and kidney damage.
How does Tarpeyo differ from other IgAN treatments?
- Tarpeyo stands out as the first drug to receive full USFDA approval for IgAN, providing a more established option compared to others with accelerated approval.
What are the expected benefits of Tarpeyo’s full approval?
- Full approval expands Tarpeyo’s accessibility, allowing a significantly larger patient population to benefit from its innovative treatment.
How does the pricing of Tarpeyo compare to its competitors?
- Tarpeyo is priced at $15,123 per month, distinguishing it from Filspari, which is priced at $9,900 per month.
Are there any potential side effects of Tarpeyo?
- Detailed information about Tarpeyo’s potential side effects should be consulted with healthcare professionals. Always refer to the drug’s official documentation for accurate and up-to-date information.

In embracing this new era of IgAN treatment, patients and healthcare professionals are encouraged to explore the potential benefits that Tarpeyo brings to the table. The journey toward addressing rare diseases takes a significant leap forward with this monumental achievement.